Table 3.
Treatment patterns by disease activity pattern
| Number of person-years (%) | p value | ||||||
|---|---|---|---|---|---|---|---|
| CA (PY = 346) | RR (PY = 1363) | LQ (PY = 2360) | Overall (PY = 4069) | (CA vs RR) | (CA vs LQ) | (LQ vs RR) | |
| Antimalarial | 307 (88.73%) | 1262 (92.59%) | 2135 (90.47%) | 3704 (91.03%) | 0.0275 | 0.3314 | 0.0301 |
| Hydroxychloroquine | 307 (88.73%) | 1262 (92.59%) | 2135 (90.47%) | 3704 (91.03%) | 0.0275 | 0.3314 | 0.0301 |
| Corticosteroids | 313 (90.46%) | 1144 (83.93%) | 1098 (46.53%) | 2555 (62.79%) | 0.0017 | < 0.0001 | < 0.0001 |
| Prednisone | 131 (37.86%) | 554 (40.65%) | 832 (35.25%) | 1517 (37.28%) | 0.3574 | 0.3672 | 0.0012 |
| Triamcinolone | 293 (84.68%) | 976 (71.61%) | 462 (19.58%) | 1731 (42.54%) | < 0.0001 | < 0.0001 | < 0.0001 |
| Methylprednisolone | 1 (0.29%) | 8 (0.59%) | 18 (0.76%) | 27 (0.66%) | 0.6963 | 0.4983 | 0.6837 |
| Immunosuppressants | 158 (45.66%) | 651 (47.76%) | 959 (40.64%) | 1768 (43.45%) | 0.5074 | 0.0795 | < 0.0001 |
| Methotrexate | 51 (14.74%) | 139 (10.20%) | 125 (5.30%) | 315 (7.74%) | 0.0212 | < 0.0001 | < 0.0001 |
| Azathioprine | 53 (15.32%) | 201 (14.75%) | 236 (10.0%) | 490 (12.04%) | 0.7997 | 0.0038 | < 0.0001 |
| Mycophenolate mofetil or mycophenolic acid | 38 (10.98%) | 302 (22.16%) | 567 (24.03%) | 907 (22.29%) | < 0.0001 | < 0.0001 | 0.1984 |
| Leflunomide | 12 (3.47%) | 20 (1.47%) | 22 (0.93%) | 54 (1.33%) | 0.0236 | 0.0006 | 0.1484 |
| Tacrolimus | 3 (0.87%) | 48 (3.52%) | 96 (4.07%) | 147 (3.61%) | 0.0071 | 0.0011 | 0.4283 |
| Cyclophosphamide | 0 | 8 (0.59%) | 19 (0.81%) | 27 (0.66%) | 0.3711 | 0.1584 | 0.5498 |
| NSAIDs | 108 (31.21%) | 375 (27.51%) | 558 (23.64%) | 1041 (25.58%) | 0.1813 | 0.0032 | 0.0096 |
| Biologics | 15 (4.34%) | 45 (3.30%) | 41 (1.74%) | 101 (2.48%) | 0.3304 | 0.0038 | 0.0030 |
| Rituximab | 6 (1.73%) | 21 (1.54%) | 18 (0.76%) | 45 (1.11%) | 0.8093 | 0.1129 | 0.0295 |
| Etanercept | 1 (0.29%) | 0 | 2 (0.08%) | 3 (0.07%) | 0.2025 | 0.3367 | 0.5357 |
| Abatacept | 2 (0.58%) | 1 (0.07%) | 0 | 3 (0.07%) | 0.1062 | 0.0163 | 0.3661 |
| Belimumab | 6 (1.73%) | 25 (1.83%) | 22 (0.93%) | 53 (1.30%) | 1.0000 | 0.1595 | 0.0217 |
A p-value < 0.05 was considered statistically significant
CA chronically active, LQ long quiescence, NSAIDs nonsteroidal anti-inflammatory drugs, PY person-years, RR relapsing–remitting